Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Interest Coverage Ratio: 2015-2023

Historic Interest Coverage Ratio for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2023 value amounting to -10.26.

  • Cartesian Therapeutics' Interest Coverage Ratio fell 414.76% to -10.26 in Q3 2023 from the same period last year, while for Sep 2023 it was -16.09, marking a year-over-year decrease of 274.22%. This contributed to the annual value of -30.50 for FY2023, which is 735.96% down from last year.
  • Cartesian Therapeutics' Interest Coverage Ratio amounted to -10.26 in Q3 2023, which was up 58.59% from -24.78 recorded in Q2 2023.
  • In the past 5 years, Cartesian Therapeutics' Interest Coverage Ratio registered a high of 19.38 during Q2 2022, and its lowest value of -79.84 during Q2 2020.
  • For the 3-year period, Cartesian Therapeutics' Interest Coverage Ratio averaged around -3.83, with its median value being -2.77 (2021).
  • Per our database at Business Quant, Cartesian Therapeutics' Interest Coverage Ratio surged by 2,949.22% in 2022 and then crashed by 414.76% in 2023.
  • Cartesian Therapeutics' Interest Coverage Ratio (Quarterly) stood at -37.52 in 2019, then surged by 70.48% to -11.08 in 2020, then surged by 151.78% to 5.74 in 2021, then tumbled by 283.55% to -10.53 in 2022, then slumped by 414.76% to -10.26 in 2023.
  • Its Interest Coverage Ratio stands at -10.26 for Q3 2023, versus -24.78 for Q2 2023 and -22.75 for Q1 2023.